Skip to content
Sign inOpen the app
Artwork for The Chain: Protein Engineering Podcast
The Chain: Protein Engineering Podcast · July 14 · 45 min

Episode: 87 - Jack Elands on How Novel ADC Payloads Could Improve Cancer Care

July 14, 2026 | Most ADCs today lean on the same Topo-1 payloads—and resistance is catching up. Jack Elands, Ph.D., founder and CEO of Adcytherix, speaks with host Rakesh Dixit, Ph.D. about what “next-generation ADCs” should mean if we care about patients, not just pipeline counts. Their conversation gets specific about where differentiation comes from: novel payloads with new mechanisms of action, better therapeutic index choices, and smarter design decisions that reduce the toxicities that make patients quit therapy early. They also pressure-test the hype around bispecific ADCs and dual-payload ADCs. Links from this episode: Adcytherix

0:00 · Welcome To The Chain-45:08
Play in podnod
Transcript file

transcript

No transcript — this publisher did not publish one.

show notes

July 14, 2026 | Most ADCs today lean on the same Topo-1 payloads—and resistance is catching up. Jack Elands, Ph.D., founder and CEO of Adcytherix, speaks with host Rakesh Dixit, Ph.D. about what “next-generation ADCs” should mean if we care about patients, not just pipeline counts. Their conversation gets specific about where differentiation comes from: novel payloads with new mechanisms of action, better therapeutic index choices, and smarter design decisions that reduce the toxicities that make patients quit therapy early. They also pressure-test the hype around bispecific ADCs and dual-payload ADCs. 

Links from this episode:  

Adcytherix 

links1

chapters

14 chapters

more episodes

All episodes